US EditionInnovent Announces a Phase 3 Study of Picankibart (Anti-IL-23p19 Antibody) Completes First Participant Dosing, Exploring Biologics Switching Treatment for Psoriasis Patients with Prior Inadequate Response to Anti-IL-17 Antibodies
- Innovent announced successful dosing of the first participant in a Phase 3 multi-center study evaluating picankibart for psoriasis patients unresponsive to anti-IL-17 antibodies as of May 28, 2025.
- This study responds to the urgent need to address biologic treatment failures in psoriasis by testing picankibart, an IL-23p19 antibody, as a switching therapy from prior ineffective IL-17 inhibitors.
- The randomized, double-blind trial plans to enroll about 310 participants, randomizing half to picankibart and half to continue IL-17 treatment, with a primary endpoint of achieving clear or almost clear skin at week 16.
- Phase 2 data showed 48.2% of patients reached the primary skin clearance endpoint, with 16.9% achieving complete clearance and response rates stable through week 44, suggesting picankibart’s potential clinical benefits.
- Picankibart’s ongoing Phase 3 trial is designed to provide strong clinical data supporting the strategy of switching biologic treatments in challenging psoriasis cases and to offer new therapeutic alternatives for individuals who have not achieved sufficient improvement with IL-17 inhibitor therapies.
Insights by Ground AI
Does this summary seem wrong?
20 Articles
20 Articles
All
Left
2
Center
6
Right
Hanford Sentinel+19 Reposted by 19other sources
Innovent Announces a Phase 3 Study of Picankibart (Anti-IL-23p19 Antibody) Completes First Participant Dosing, Exploring Biologics Switching Treatment for Psoriasis Patients with Prior Inadequate Response to Anti-IL-17 Antibodies
SAN FRANCISCO and SUZHOU, China, May 28, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major…
Coverage Details
Total News Sources20
Leaning Left2Leaning Right0Center6Last UpdatedBias Distribution75% Center
Bias Distribution
- 75% of the sources are Center
75% Center
L 25%
C 75%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
